Peri-operative Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

October 31, 2015

Conditions
Disorder Related to Lung Transplantation
Interventions
DRUG

Azithromycin

"Zithromax® oral suspension 200 mg/ 5 mL (Pfizer, UK):~Zithromax® 1000 mg syrup per os once at recipient intake for lung transplantation (day 0); followed by Zithromax® 250 mg syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."

DRUG

Ora-Plus

"Ora-Plus® oral suspension (Paddock Laboratories, 3940 Quebec Avenue N, Minneapolis, MN 55427, USA; NDC-number: 0574-0303-16):~Ora-Plus® 25mL syrup per os once at recipient intake for lung transplantation (day 0); followed by Ora-Plus® 6.25 mL syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."

Trial Locations (1)

B-3000

University Hospitals Leuven, Leuven

All Listed Sponsors
collaborator

Fund for Scientific Research, Flanders, Belgium

OTHER

collaborator

KU Leuven

OTHER

lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT01915082 - Peri-operative Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation | Biotech Hunter | Biotech Hunter